CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis

por Agostinetto, E., Vian, L., Caparica, R., Bruzzone, M., Ceppi, M., Lambertini, M., Pondé, N., de Azambuja, E.
Publicado 2021

Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial

por de Azambuja, E., Agostinetto, E., Procter, M., Eiger, D., Pondé, N., Guillaume, S., Parlier, D., Lambertini, M., Desmet, A., Caballero, C., Aguila, C., Jerusalem, G., Walshe, J.M., Frank, E., Bines, J., Loibl, S., Piccart-Gebhart, M., Ewer, M.S., Dent, S., Plummer, C., Suter, T.
Publicado 2023